HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Industry still cares about switching

This article was originally published in OTC Bulletin & The Rose Sheet

Executive Summary

Industry was “absolutely interested in switches”, insisted Dirk Ossenberg-Engels, head of Bayer Consumer Health’s Europe South, Central Eastern Europe and Middle East business unit, after the sector’s commitment to prescription-to-OTC reclassification was challenged by Christa Wirthumer-Hoche, chair of the management board of the European Medicines Agency (EMA).


Related Content

An Expert’s Guide To Switching In Germany, Part 2: Improving The Reclassification Process





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts